Acalabrutinib - OmicsDI

Show results for

Unknown (196)
Genomics (14)
Transcriptomics (9)
Metabolomics (6)
Proteomics (4)

Organisms

Homo sapiens (8)
Alphavirus (4)
Archaea (4)
Bacteria (4)
Betaherpesvirinae (4)
Borrelia (4)
Botrytis cinerea (4)
Chlorella vulgaris (4)
Clostridium perfringens (4)
Enterovirus A71 (4)
Eukaryota (4)
Fungi (4)
Hepatitis B virus (4)
Human betaherpesvirus 5 (4)
Influenza A virus (4)
Influenza C virus (4)
Japanese encephalitis virus group (4)
Listeria monocytogenes (4)
Mammarenavirus (4)
Miscanthus x giganteus (4)
Mycobacterium tuberculosis (4)
Orthoflavivirus (4)
Panicum virgatum (4)
Pseudomonas aeruginosa (4)
Rattus (4)
Schizosaccharomyces (4)
Severe acute respiratory syndrome coronavirus 2 (4)
Staphylococcus aureus (4)
Streptococcus pneumoniae (4)
Mus musculus (1)

Organisms

Homo sapiens (10)
Mus musculus (2)

Repository

ENA (14)
geo (9)
MetaboLights (6)
pride (4)

Tissue

B cell (2)
Cell culture (1)
Epithelial cell (1)
Epithelial cell of alveolus of lung (1)

Disease

Diffuse large B-cell lymphoma (1)
Skin cancer (1)

Technology Type

Mass spectrometry assay (4)
Mass Spectrometry (4)
Mass spectrometry (2)
Shotgun proteomics (2)
Bottom-up proteomics (1)
Data-dependent acquisition (1)
Gel-based experiment (1)
HDMSE (1)

Instrument Platform

Liquid Chromatography MS - alternating - reverse-phase (3)
Liquid Chromatography MS - positive - direct infusion (1)
Liquid Chromatography MS - negative - direct infusion (1)
Liquid Chromatography MS - positive - reverse-phase (1)
Liquid Chromatography MS - negative - reverse-phase (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

CHEBI ID

CHEBI:17563 (1)
CHEBI:495055 (1)
CHEBI:181348 (1)
CHEBI:17180 (1)
CHEBI:181179 (1)
CHEBI:15589 (1)
CHEBI:17504 (1)
CHEBI:182763 (1)
CHEBI:182404 (1)
CHEBI:81233 (1)
CHEBI:181111 (1)
CHEBI:27934 (1)
CHEBI:15341 (1)
CHEBI:15685 (1)
CHEBI:15748 (1)
CHEBI:16064 (1)
CHEBI:D07342 (1)
CHEBI:29934 (1)
CHEBI:D01422 (1)
CHEBI:15404 (1)
CHEBI:181398 (1)
CHEBI:28383 (1)
CHEBI:1310 (1)
CHEBI:28369 (1)
CHEBI:3524 (1)
CHEBI:31591 (1)
CHEBI:355715 (1)
CHEBI:229813 (1)
CHEBI:66557 (1)
CHEBI:15812 (1)

Metabolite Name

Acalabrutinib (6)
Prolylhydroxyproline (6)
L-Phenylalanine (6)
Aspartylphenylalanine (5)
Pirbuterol (5)
5'-Methylthioadenosine (5)
Erucic acid (5)
Palmitoylethanolamide (5)
L-Histidine (5)
Decanoylcarnitine (5)
Choline (5)
L-Arginine (5)
L-Lysine (5)
L-Glutamic acid (5)
Dodecanamide (5)
Adenosine (5)
Riboflavin (5)
L-Glutamine (5)
Thymidine (5)
Biotin (5)
L-Methionine (5)
Prulaurasin (4)
Methionyl-Proline (4)
N-Palmitoyl Alanine (4)
Nalmefene (4)
N-Palmitoyl Tryptophan (4)
Crotonoside (4)
D-Tyrosine (4)
Brexpiprazole (4)
Imidazole acetol-phosphate (4)

First Public Date

2026 (4)
2022 (4)
2023 (3)
2020 (2)
2024 (1)

Release Date

2022 (35)
2021 (35)
2023 (32)
2025 (26)
2020 (25)
2024 (16)
2018 (8)
2019 (7)
2017 (7)
2016 (3)
2026 (2)

Lab affiliation

Cellzome (1)
KU Leuven – University of Leuven, Laboratory of Chemical Biology, Department of Cellular and Molecular Medicine, Herestraat 49 box 901b, 3000 Leuven, Belgium (1)
Lymphoid Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda, Maryland (1)
Northeastern University (1)

Publication date

2026 (7)
2024 (3)
2025 (3)
2022 (2)
2020 (2)
2023 (1)
2017 (1)

Tags

xref:PubMed:38215749 (1)
xref:PubMed:32202637 (1)
xref:PubMed:37184294 (1)
xref:PubMed:42367798 (1)

Previous page
1 / 23
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 23
Next page

Sort by:

Relevance

Page size

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

PRJNA1365024 | ENA

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the only curative option for certain malignant hematopoietic disorders, yet its benefits are limited by the developmentof graft-versus-host disease (GVHD). Chronic GVHD (cGVHD) is often characterized by chronic inflammation...

ORGANISM(S): Mus musculus

2026-07-01 | GSE310029 | GEO

Clinical and biological implications of target occupancy in chronic lymphocytic leukemia treated with acalabrutinib

PRJNA562903 | ENA

Acalabrutinib in treatment-naive chronic lymphocytic leukemia.

Not available

S-EPMC8670015 | biostudies-literature

Ventricular arrhythmias and sudden death events following acalabrutinib initiation.

Not available

S-EPMC10405526 | biostudies-literature

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.

Not available